知镜 Cognispect · 医学文献与研究工作台

Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities.

Abt ER, Radu CG, Czernin J, Mona CE.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026-09-11 · PMID 42728104

文献摘要

Radiopharmaceutical therapy (RPT) has transformed the management of metastatic castration-resistant prostate cancer and neuroendocrine tumors, with clinical development extending to renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. Because relapse after RPT occurs across cancer types, there is an urgent need to implement new treatment strategies to overcome resistance and achieve more durable responses. Here, we summarize recent advances in research concerning RPT resistance mechanisms involving tumor cell-intrinsic signaling, the tumor immune microenvironment, and tumor metabolism, as well as emerging strategies to overcome them. We also highlight progress in advanced preclinical models that better recapitulate human metabolism and immune responses, which are essential for validating new combination approaches designed to maximize the clinical benefit of RPT, with a focus on prostate cancer.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。